Answer
Gastrointestinal perforations have been reported with upadacitinib hemihydrate in clinical trials and post-marketing reports; caution is advised in patients at risk, and new abdominal signs or symptoms require prompt evaluation.
Sources for this answer
- RINVOQ 15 mg prolonged-release tabletsAbbVie Ltd · emc · SmPC §4.4 Special warnings and precautions for use · Version 28Document updated
Sources checked